Cibc World Market Inc. Anavex Life Sciences Corp. Transaction History

Cibc World Market Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	SELL	$3.39 - $5.02 $2,118 - $3,137	-625 Reduced 4.22%	14,187 $60,000
Q1 2024 May 13, 2024	SELL	$4.55 - $6.75 $2,206 - $3,273	-485 Reduced 3.17%	14,812 $75,000
Q4 2023 Feb 13, 2024	SELL	$5.04 - $9.95 $2,499 - $4,935	-496 Reduced 3.14%	15,297 $142,000
Q3 2023 Nov 13, 2023	SELL	$6.55 - $9.37 $406 - $580	-62 Reduced 0.39%	15,793 $103,000
Q2 2023 Aug 11, 2023	SELL	$7.66 - $9.5 $1,401 - $1,738	-183 Reduced 1.14%	15,855 $129,000
Q1 2023 May 12, 2023	SELL	$8.32 - $11.75 $1,206 - $1,703	-145 Reduced 0.9%	16,038 $137,000
Q4 2022 Feb 13, 2023	SELL	$7.65 - $14.43 $1,040 - $1,962	-136 Reduced 0.83%	16,183 $150,000
Q3 2022 Nov 10, 2022	SELL	$8.9 - $12.86 $1,370 - $1,980	-154 Reduced 0.93%	16,319 $168,000
Q2 2022 Aug 10, 2022	BUY	$7.31 - $12.84 $899 - $1,579	123 Added 0.75%	16,473 $165,000
Q1 2022 May 12, 2022	BUY	$9.74 - $17.69 $935 - $1,698	96 Added 0.59%	16,350 $201,000
Q4 2021 Feb 14, 2022	BUY	$16.88 - $23.31 $8,726 - $12,051	517 Added 3.29%	16,254 $282,000
Q3 2021 Nov 12, 2021	BUY	$16.82 - $25.75 $264,696 - $405,227	15,737 New	15,737 $282,000

154

27.3M

515K

838K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $581M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Cibc World Market Inc., based on Form 13F filings with the SEC.

Stay updated on Cibc World Market Inc. with notifications on news.